NCT07201376View on ClinicalTrials.gov

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Not yet recruitingOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Non-Melanoma Skin Cancer (NMSC)Benign Skin Growth
Interventions
DRUG

Ameluz 10% Topical Gel

One-time topical application of 10% Ameluz gel for up to 1 hour

DEVICE

Protoporphyrin IX

Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.

All Listed Sponsors
collaborator

Dartmouth College

OTHER

lead

Dartmouth-Hitchcock Medical Center

OTHER